Evidence map›Paper›PMID 26351277›Full record

ArticleInfection and immunity2015

STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans.

Chrissy M Leopold Wager, Camaron R Hole, Karen L Wozniak, Michal A Olszewski, Mathias Mueller, Floyd L Wormley

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 95 citations in OpenAlex.

  1. Extracellular Vesicles fromJournal of fungi (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Inbred Mouse Models inJournal of fungi (Basel, Switzerland) · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Innate Pulmonary Phagocytes and Their Interactions with PathogenicJournal of fungi (Basel, Switzerland) · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Journal of fungi (Basel, Switzerland) · 2022
    Review
  20. Journal of fungi (Basel, Switzerland) · 2022
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Chrissy M Leopold WagerDepartment of Biology, The University of Texas at San Antonio, San Antonio, Texas, USA The South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Camaron R HoleDepartment of Biology, The University of Texas at San Antonio, San Antonio, Texas, USA The South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Karen L WozniakDepartment of Biology, The University of Texas at San Antonio, San Antonio, Texas, USA The South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA.
Michal A OlszewskiVA Ann Arbor Health System, University of Michigan Health System, Ann Arbor, Michigan, USA Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA.
Mathias MuellerInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria.
Floyd L WormleyDepartment of Biology, The University of Texas at San Antonio, San Antonio, Texas, USA The South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, Texas, USA floyd.wormley@utsa.edu.
Texas Center for Infectious Disease · USUniversity of Veterinary Medicine Vienna · ATVA Ann Arbor Healthcare System · US

Funding

Protective Host Immunity Against Pulmonary CryptococcosisR01AI071752 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI WORMLEY, FLOYD L. · 2007 to 2018
$3.7M
Induction of Protection Against Cryptococcus neoformans in Immune Deficient HostsR21AI100893 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI WORMLEY, FLOYD L. · 2012 to 2013
$393k
Modulation of Pulmonary Defenses in Pathobiology of Chronic InfectionsI01BX000656 · VA · VETERANS HEALTH ADMINISTRATION · PI OLSZEWSKI, MICHAL A · 2011 to 2025
–
BLRD VA I01 BX000656NIAID NIH HHS 2R01AI071752NIAID NIH HHS R01 AI071752NIAID NIH HHS R21 AI100893NIAID NIH HHS R21AI100893
6 · The paper itself

Abstract

Cryptococcus neoformans, the predominant etiological agent of cryptococcosis, is an opportunistic fungal pathogen that primarily affects AIDS patients and patients undergoing immunosuppressive therapy. In immunocompromised individuals, C. neoformans can lead to life-threatening meningoencephalitis. Studies using a virulent strain of C. neoformans engineered to produce gamma interferon (IFN-γ), denoted H99γ, demonstrated that protection against pulmonary C. neoformans infection is associated with the generation of a T helper 1 (Th1)-type immune response and signal transducer and activator of transcription 1 (STAT1)-mediated classical (M1) macrophage activation. However, the critical mechanism by which M1 macrophages mediate their anti-C. neoformans activity remains unknown. The current studies demonstrate that infection with C. neoformans strain H99γ in mice with macrophage-specific STAT1 ablation resulted in severely increased inflammation of the pulmonary tissue, a dysregulated Th1/Th2-type immune response, increased fungal burden, deficient M1 macrophage activation, and loss of protection. STAT1-deficient macrophages produced significantly less nitric oxide (NO) than STAT1-sufficient macrophages, correlating with an inability to control intracellular cryptococcal proliferation, even in the presence of reactive oxygen species (ROS). Furthermore, macrophages from inducible nitric oxide synthase knockout mice, which had intact ROS production, were deficient in anticryptococcal activity. These data indicate that STAT1 activation within macrophages is required for M1 macrophage activation and anti-C. neoformans activity via the production of NO.

Indexed as

AnimalsCryptococcosisCryptococcus neoformansGene Expression RegulationHost-Pathogen InteractionsHumansLungLung Diseases, FungalMacrophage ActivationMacrophages, AlveolarMiceMice, Inbred BALB CMice, TransgenicNitric OxideNitric Oxide Synthase Type IIReactive Oxygen SpeciesNitric OxideNitric Oxide Synthase Type IINos2 protein, mouseReactive Oxygen SpeciesStat1 protein, mouseSTAT1 Transcription Factor

Identifiers

PMID26351277
PMCPMC4645398
OpenAlexW2173068170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.